Metabolic Modulation in Hypertrophic Cardiomyopathy: A Systematic Review of Clinical and Observational Evidence
In brief
Small studies link metabolic drugs to symptom relief, not better exercise capacity
Across seven studies in hypertrophic cardiomyopathy, perhexiline improved exercise capacity and symptoms, while trimetazidine was neutral and ranolazine eased angina and ventricular ectopy without boosting peak oxygen uptake. A small cohort linked sodium-glucose cotransporter 2 inhibitors to better diastolic measures and symptoms, while a diabetic registry linked their use to fewer deaths and heart-failure admissions; larger trials are needed to clarify their role.
- Journal
- European cardiology (Q1)
- Published
- 2 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Shun Wen Chew, Jasmine Cheong Zhen Yi, Samuel Lim Jian Rong, Nicholas Yip Zhe Wei, Mohd Shawal Faizal Mohamad, Chim C Lang, et al.
- PMID
- 43022434
- DOI
- 10.15420/ecr.2025.94
Why clinicians should know about it
- Picked for Biochemistry (medical) (paper of the day, 16 November 2026): Human cardiac energy metabolism and metabolic biomarkers
Abstract
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is characterised by left ventricular hypertrophy, microvascular dysfunction and chronic energetic inefficiency. Current therapies relieve symptoms or left ventricular outflow tract obstruction but do not directly target these metabolic abnormalities. METHODS: We systematically searched PubMed, Embase, Google Scholar and ClinicalTrials.gov from 1 January 2000 to 31 May 2025 for randomised trials, observational cohorts, registries and case series (≥3 patients) evaluating fatty acid oxidation inhibitors (perhexiline, trimetazidine), late sodium current inhibition (ranolazine) or sodium-glucose cotransporter 2 inhibitors (SGLT2I) in adults with HCM. Outcomes included exercise capacity, diastolic indices, symptoms, arrhythmia burden and safety. RESULTS: Seven HCM-specific studies met inclusion criteria: trimetazidine (one randomised controlled trial [RCT]), perhexiline (one RCT), ranolazine (one RCT, one real-world cohort and one case series) and SGLT2I (one prospective controlled cohort, one nationwide registry). Most enrolled predominantly non-obstructive or mixed HCM. Trimetazidine had neutral effects on peak VO₂, diastolic function and biomarkers. Perhexiline improved phosphocreatine-to-adenosine triphosphate ratios, diastolic indices, peak VO₂ and New York Heart Association class. Ranolazine consistently reduced angina and ventricular ectopy but did not increase peak VO₂. In the included HCM studies, empagliflozin/dapagliflozin exposure in a small prospective cohort was associated with improved E/e' and New York Heart Association class, while broader SGLT2I use in a diabetic HCM registry was associated with lower mortality and hospitalisation for heart failure. CONCLUSION: Metabolic modulators and SGLT2I could improve diastolic parameters, symptoms and arrhythmia burden in selected, mainly non-obstructive HCM populations but have not demonstrated consistent gains in exercise capacity. Larger, phenotype-stratified randomised trials are needed to define their role alongside contemporary HCM therapies.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.